Cart
sales@molnova.com
3-O-p-Coumaroylquinic acid
CAS No. 5746-55-4
3-O-p-Coumaroylquinic acid( —— )
Catalog No. M29439 CAS No. 5746-55-4
3-O-p-Coumaroylquinic acid, hydroxycinnamic acid derivative, is isolated from a 70% methanolic Crataegus extract (Crataegi folium cum flore).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 223 | In Stock |
|
| 5MG | 215 | In Stock |
|
| 10MG | 345 | In Stock |
|
| 25MG | 560 | In Stock |
|
| 50MG | 795 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name3-O-p-Coumaroylquinic acid
-
NoteResearch use only, not for human use.
-
Brief Description3-O-p-Coumaroylquinic acid, hydroxycinnamic acid derivative, is isolated from a 70% methanolic Crataegus extract (Crataegi folium cum flore).
-
Description3-O-p-Coumaroylquinic acid, hydroxycinnamic acid derivative, is isolated from a 70% methanolic Crataegus extract (Crataegi folium cum flore).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number5746-55-4
-
Formula Weight674.6
-
Molecular FormulaC32H34O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO[C@H](C[C@](C[C@H]1OC(/C=C/c(cc2)ccc2O)=O)(C(O)=O)O)[C@H]1OO[C@H](C[C@](C[C@H]1OC(/C=C/c(cc2)ccc2O)=O)(C(O)=O)O)[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
5-MethoxyPinocembros...
5-MethoxyPinocembroside is a flavonoid isolated from the leaves of [Moringa oleifera].
-
Timosaponin A1
Timosaponin A1 is a coprostane type steroidal saponin isolated from Rhizoma Anemarrhenae.
-
Atracurium besylate
Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
